Progress in Neurotherapeutics and Neuropsychopharmacology: Volume 2, 2007


Book Description

Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.







From Sin to Disease


Book Description

Since Benjamin Rush first introduced the disease of wills as the cause of alcoholism, a steady and slow infiltration of the disease model has infected how the church treats those who struggle with addictions. The first organization that truly sought to remove the soul care of addicts from the church was Alcoholics Anonymous (AA), through their bestselling The Big Book of AA and the introduction of the 12 Steps. AA’s influence on how the church confronts addiction still reverberates today, with many of the ministries that address addiction firmly rooted in what can be found in AA literature. Addictions were once viewed as an issue caused by sin and best addressed through faith and prayer. Currently addiction is seen through the lens of disease. The ramifications are consequential as more church members are struggling with addictions than ever before. Tracing the progression of addiction from sin to disease will reveal that the SBC and its churches have been negligent in understanding the underlying foundations of AA and the influence that the medicalization of substance abuse has had on how churches approach what should be classified as a sin issue.




Polypharmacy in Psychiatry


Book Description

This practical reference examines the advantages and disadvantages of polypharmacy in psychiatry, and provides up-to-date clinical guidelines on the appropriate use of combinations of pharmacological therapy in major psychiatric disorders-including multidisciplinary approaches to treatment, such as social work and psychopharmacology, and an examina







Progressive Brain Disorders in Childhood


Book Description

A review of childhood neurodegenerative and other progressive but non-degenerative disorders to guide their diagnosis and management.




Rapid Acting Antidepressants


Book Description

The Advances in Pharmacology series presents a variety of chapters from the best authors in the field. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series




Pain Management and the Opioid Epidemic


Book Description

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.




Handbook of Neuroscience for the Behavioral Sciences, Volume 2


Book Description

As technology has made imaging of the brain noninvasive and inexpensive, nearly every psychologist in every subfield is using pictures of the brain to show biological connections to feelings and behavior. Handbook of Neuroscience for the Behavioral Sciences, Volume II provides psychologists and other behavioral scientists with a solid foundation in the increasingly critical field of neuroscience. Current and accessible, this volume provides the information they need to understand the new biological bases, research tools, and implications of brain and gene research as it relates to psychology.